TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price traded down 29.5% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.14. 15,304 shares were traded during trading, a decline of 77% from the average session volume of 67,568 shares. The stock had previously closed at $0.20.
TC Biopharm Trading Down 29.5 %
The business has a fifty day moving average price of $0.13 and a 200-day moving average price of $0.18.
Get TC Biopharm alerts:Institutional Investors Weigh In On TC Biopharm
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC purchased a new stake in TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 235,294 shares of the company's stock, valued at approximately $117,000.
About TC Biopharm
(Get Rating)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
See Also
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- Palo Alto Networks Is The Leading Cyber Security Play
- It's Not Time To Buy Toll Brothers, Inc Yet
- Why You Absolutely Must Buy Dividend Stocks This Year
- Furniture Stocks: A Comfortable Way To Ride Out The Storm
- JD.com Getting Desperate or Too Smart for Anyone to Figure Out?
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.